ANN ARBOR – An investment made by several groups of early-stage Michigan investors could pay off in a big way following the recent news that Allergan acquired Ann Arbor-based RetroSense Therapeutics LLC, a Michigan angel-backed gene therapy company, for $60 million plus additional funding if the company reaches future milestones.
Terry Cross, MVCA member, and director of RetroSense Therapeutics feels confident these hurdles can be cleared. “Are milestones hard? Yes, but, we have a modest degree of confidence that we can meet these milestones within the next five years,” he said. “ The most remarkable thing, however, is that this product is giving sight to blindness.”
To read more of this story published by the Michigan Venture Capital Association, click on http://michiganvca.org/investorsseeexitbrightfutureahead/
